The escalating conflict involving Iran has significantly disrupted the transportation of essential pharmaceuticals to the Gulf region, raising serious concerns about the steady supply of critical cancer drugs and other temperature-sensitive treatments. This turmoil stems from recent military actions initiated by the United States and Israel against Iran, which have triggered retaliatory strikes by Iran across the Middle East. These hostilities have led to the shutdown of key air transit hubs and maritime routes, complicating the movement of vital goods ranging from medicines to food and oil.
Given the Gulf’s heavy dependence on imports for its pharmaceutical needs, the disruption poses a unique challenge, especially for medicines that require strict cold-chain storage to maintain their efficacy. Many cancer drugs, including monoclonal antibodies, have limited shelf lives and must be kept within precise temperature ranges during transit. Lengthy overland transportation, while a possible alternative, is less practical due to these stringent storage requirements. As a result, pharmaceutical companies are urgently exploring alternative logistics pathways, including rerouting flights and utilizing overland trucking from airports in Saudi Arabia such as Jeddah and Riyadh, as well as ports in Oman and hubs like Istanbul.
The closure of major Gulf airports, notably Dubai, Abu Dhabi, and Doha, has been a direct consequence of Iranian missile and drone strikes aimed at retaliating against U.S. and Israeli military operations. These airports serve as critical cargo hubs connecting Europe with Asia and Africa, with airlines such as Emirates and Etihad, alongside logistics firms like DHL, handling large volumes of temperature-controlled pharmaceutical shipments. The sudden loss of these transit points has forced companies to devise complex rerouting strategies to ensure that sensitive medicines reach patients without compromising their quality.
Experts highlight that over 20% of global air cargo, which is the primary mode for transporting life-saving drugs and vaccines, passes through the Middle East. This statistic underscores the vulnerability of the pharmaceutical supply chain to regional instability. However, establishing new cold-chain corridors is a complex and time-consuming process that cannot be implemented instantly. Pharmaceutical executives have formed dedicated teams to prioritize shipments critical to patient care, focusing especially on oncology treatments. They emphasize the importance of maintaining proper storage and handling throughout the journey to prevent any loss of drug potency.
In addition to air freight challenges, maritime routes have also been compromised. The closure of the Strait of Hormuz, a vital shipping lane, has rendered sea transport less viable due to extended transit times and increased risks. This situation leaves companies with few options other than air and overland routes, which are themselves fraught with logistical hurdles. Medical device companies are actively tracking shipments already in transit and making real-time decisions about diverting cargo or rescheduling dispatches to mitigate delays.
Although Dubai International Airport has started to resume operations following a temporary shutdown caused by a drone attack-induced fuel tank fire, the overall situation remains precarious. Some cargo that typically moves through Dubai or Doha is now being rerouted via alternative hubs such as China and Singapore. These detours inevitably lead to longer transit times and increased transportation costs, including higher fuel consumption and the need for additional cooling materials like dry ice to maintain drug integrity.
Healthcare experts warn that if the conflict persists, hospitals across the Gulf could face shortages of critical medicines within weeks. Stocks of temperature-sensitive and costly drugs, particularly those used in cancer treatment, generally last about three months under normal circumstances. Delays in delivery could force patients to restart therapies or face worsening health outcomes. Industry stakeholders recently convened in a webinar hosted by Pharma.Aero, a life sciences logistics consortium, to discuss the ongoing crisis and strategize on mitigating supply chain disruptions.
Despite these challenges, some logistics providers remain cautiously optimistic. Companies like Kuehne+Nagel have adapted by prioritizing healthcare cargo and utilizing alternative airports and land routes to maintain supply lines. However, the situation demands constant vigilance and rapid adjustments as airspace restrictions and geopolitical tensions evolve. The increased complexity and cost of transportation are significant concerns, but ensuring uninterrupted access to life-saving medicines remains the top priority for all involved.
Beyond the medicines themselves, the conflict threatens the availability of ancillary components essential for pharmaceutical packaging and administration, such as vial stoppers and IV bag plastics. Shortages in these materials could indirectly disrupt drug supplies, highlighting the fragility of the entire supply chain. Industry analysts emphasize that the crisis is not solely about the drugs but also about the small yet vital parts that enable their safe and effective use.
